Skip to main content

Treatment Clinical Trials for Pancreatic Cancer

Review the pancreatic cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 176-200 of 225

CBP-1019 with FOLFOX with or without Bevacizumab, Pembrolizumab, or Enzalutamide for the Treatment of Metastatic Solid Tumors of Epithelial Origin
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
PRMT5 Inhibition with BMS-986504 and PARP Inhibition with Olaparib for the Treatment of Advanced and Metastatic Solid Tumors with MTAP Loss
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Intraperitoneal Paclitaxel with NALIRIFOX for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Ductal Adenocarcinoma with Peritoneal Carcinomatosis
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Status: Active
Location: 4 locations
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
Status: Active
Location: 2 locations
gFOLFOXIRITAX Regimen for the Treatment of Locally Advanced or Metastatic Upper Gastrointestinal Adenocarcinoma, I-FLOAT Study
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Status: Active
Location: 2 locations
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Camelid Nanobody B7-H3 Tri-Specific Killer Engager (GTB-5550) for the Treatment of Advanced Solid Tumors that Failed Prior Therapy
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Fecal Microbial Transplants for the Treatment of Pancreatic Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
High-Dose Omeprazole for the Treatment of Patients with Pancreatic Cancer before Surgery, OMEPRAZOLEPANC Trial
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Surgical Resection after Chemotherapy for the Treatment of Pulmonary or Hepatic Oligometastatic Pancreatic Cancer
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Status: Active
Location: See ClinicalTrials.gov
Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
Status: Active
Location: See ClinicalTrials.gov
A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov